Search

ImmunityBio Inc

Aperta

SettoreSettore sanitario

8.49 0.59

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

8.19

Massimo

8.78

Metriche Chiave

By Trading Economics

Entrata

-230M

-863M

Vendite

7M

51M

EPS

-0.08

Margine di Profitto

-1,684.596

Dipendenti

684

EBITDA

378M

-222M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+53.66% upside

Dividendi

By Acuity

Utili prossimi

2 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.4B

8.9B

Apertura precedente

7.9

Chiusura precedente

8.49

Notizie sul Sentiment di mercato

By Acuity

50%

50%

125 / 339 Classifica in Healthcare

ImmunityBio Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 set 2026, 20:02 UTC

Social Media

ImmunityBio Inc is trading sharply higher, nearing $12, amid notable social media attention and unusually high market volume, despite a slight pullback earlier in the session.

16 set 2026, 20:10 UTC

Immunitybio Inc shares are declining, remaining below their 20-day moving average, following a notable early high in Wednesday's trading session.

15 set 2026, 23:01 UTC

Immunitybio Inc shares are lower in after-market trading. Broader market sentiment may be affected by a significant decline in the New York Empire State Manufacturing Index.

14 set 2026, 20:08 UTC

Social Media
News

ImmunityBio Inc is gaining as it participates in key cancer conferences this week and files a patent for Anktiva to enhance immune response.

11 set 2026, 20:03 UTC

News

ImmunityBio Inc is higher as it prepares for key presentations at upcoming conferences and highlights potential uses for Anktiva in cancer treatment.

10 set 2026, 19:36 UTC

News

ImmunityBio shares are lower as Bronstein, Gewirtz & Grossman, LLC announces an investigation into potential corporate wrongdoing targeting prior investors.

9 set 2026, 23:01 UTC

Immunitybio Inc. shares declined after hours, reflecting a notable drop from an earlier session high amid no specific company news identified.

8 set 2026, 23:16 UTC

Immunitybio Inc shares are lower in after-market hours, with no specific news identified. Broader market weakness is attributed to geopolitical tensions in the Middle East.

3 set 2026, 19:26 UTC

Immunitybio Inc's shares are higher today, reflecting positive market sentiment amid declining Treasury yields and easing labor market concerns.

2 set 2026, 23:06 UTC

Immunitybio Inc shares are lower in after-market trading, with no specific news identified. The broader market reacted to a weaker ADP payrolls report.

31 ago 2026, 20:07 UTC

Immunitybio Inc shares are lower amid broader market pressures and rising bond yields following comments from Warsh at the Jackson Hole Economic Symposium.

29 ago 2026, 00:01 UTC

Immunitybio Inc shares are higher in after-market trading, though no specific news was identified for the price movement. The stock remains near its one-month range high.

28 ago 2026, 20:02 UTC

Immunitybio Inc. shares are lower today, reflecting broader market trends amid rising U.S. Treasury yields. The stock remains above its 20-day moving average.

27 ago 2026, 23:01 UTC

Immunitybio Inc. traded roughly flat after-market, despite earlier gains. Broader market trends reflected mixed trading and inflation concerns ahead of a key Fed speech.

26 ago 2026, 19:16 UTC

News
Social Media

ImmunityBio Inc. shares are trading higher as institutional interest grows, with Virginia Retirement System holding 74,500 shares and promising trial data for Anktiva.

24 ago 2026, 20:06 UTC

Immunitybio Inc's shares are lower today, continuing a decline over three trading days. Broader market sentiment is impacted by rising oil prices and geopolitical tensions.

21 ago 2026, 19:16 UTC

Immunitybio Inc. shares are lower today amid rising crude oil prices and geopolitical tensions, despite remaining above their 20-day moving average.

20 ago 2026, 23:06 UTC

Immunitybio Inc. shares are lower in after-market trading, declining since Thursday's close. The asset remains above its 20-day moving average.

19 ago 2026, 19:26 UTC

Social Media

Immunitybio Inc shares are higher Wednesday, buoyed by social media discussions anticipating prices between $8 and $12. The stock remains above its 20-day moving average.

18 ago 2026, 23:06 UTC

Immunitybio Inc shares are lower in after-market hours, with no specific news identified. Broader market conditions reflect a decline in U.S. stocks.

14 ago 2026, 19:36 UTC

Immunitybio shares are lower amid broader market sentiment following a reported decline in retail sales, raising concerns about consumer demand and economic health.

10 ago 2026, 19:16 UTC

News

ImmunityBio Inc. appoints Dr. Jim Yong Kim as Vice Chairman. Shares are lower today amid broader market pressure from a U.S. jobs report.

7 ago 2026, 23:06 UTC

Immunitybio Inc's shares are lower in after-market hours, with no specific news driving the decline. The stock remains above its 20-day moving average.

6 ago 2026, 23:11 UTC

Immunitybio Inc's shares are higher in after-market trading, reflecting a slight increase since Thursday's close, though still below the 20-day moving average.

5 ago 2026, 19:26 UTC

Immunitybio Inc's shares are higher today amid positive market sentiment. The stock is recovering from earlier weakness despite remaining below its 20-day moving average.

4 ago 2026, 23:46 UTC

Immunitybio Inc. shares are trading roughly flat in after-market hours. The asset remains significantly below its 20-day moving average.

3 ago 2026, 23:21 UTC

Immunitybio Inc shares rose in after-market trading, settling higher since Monday's close. The stock remains below its 20-day moving average.

1 ago 2026, 00:02 UTC

Immunitybio Inc shares are higher in after-market trading, reflecting a notable increase since Friday's close amid broader market dynamics.

31 lug 2026, 23:06 UTC

Immunitybio Inc's shares are higher in after-market trading, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

30 lug 2026, 19:29 UTC

Immunitybio Inc is trading higher, recovering from an earlier drop. The stock has rebounded significantly since Wednesday's close, despite six consecutive lower daily closes.

Confronto tra pari

Modifica del prezzo

ImmunityBio Inc Previsione

Obiettivo di Prezzo

By TipRanks

53.66% in crescita

Previsioni per 12 mesi

Media 13 USD  53.66%

Alto 15 USD

Basso 12 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per ImmunityBio Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

125 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.